|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
1997-1-31
|
|
pubmed:abstractText |
Efficacy and safety of therapy with lymphoblastoid interferon-alpha alone or combined with deflazacort has been investigated in 38 HBsAg-HBeAg+ patients with biopsy-proven chronic hepatitis. Group I received 5 MU/m2 interferon thrice a week for 26 weeks; group II took interferon for 26 weeks simultaneously with a 6-week course of deflazacort. Follow-up was 18-72 months (median 42). After 12 months, responses were achieved in 3 (18%) out of 17 patients on interferon alone vs 5 (26%, p > 0.05) out of 19 on combined therapy. Blind histological assessment revealed no improvement in either group or in patients who responded to therapy within the first year of follow-up ("early responders"). "Delayed" responses were observed in 4 (29%) patients who took interferon alone vs 5 (36%, p > 0.05) who took the combined therapy. Serum HBV DNA levels decreased significantly during treatment and remained low up to 24 and 36 months of follow-up in both groups. One early responder developed hepatocellular carcinoma, another had exacerbation of liver disease in long-term follow-up. No non-responders developed liver failure or hepatocellular carcinoma. These results indicate that lymphoblastoid interferon-alpha inhibits HBV replication and corticosteroids have no synergistic effect in treatment of HBsAg-HBeAg+ chronic hepatitis.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Anti-Inflammatory Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Viral,
http://linkedlifedata.com/resource/pubmed/chemical/Antiviral Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Biological Markers,
http://linkedlifedata.com/resource/pubmed/chemical/DNA, Viral,
http://linkedlifedata.com/resource/pubmed/chemical/Hepatitis B Surface Antigens,
http://linkedlifedata.com/resource/pubmed/chemical/Hepatitis B e Antigens,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-alpha,
http://linkedlifedata.com/resource/pubmed/chemical/Pregnenediones,
http://linkedlifedata.com/resource/pubmed/chemical/deflazacort
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0392-0623
|
|
pubmed:author |
pubmed-author:AsteHH,
pubmed-author:BellatiGG,
pubmed-author:BottelliRR,
pubmed-author:FesceEE,
pubmed-author:GelosaFF,
pubmed-author:IamoniGG,
pubmed-author:IdeoGG,
pubmed-author:MaggiGG,
pubmed-author:MondazziLL,
pubmed-author:TanziEE,
pubmed-author:ZanettiAA,
pubmed-author:ZavagliaCC
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
28
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
324-31
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:8891847-Adult,
pubmed-meshheading:8891847-Anti-Inflammatory Agents,
pubmed-meshheading:8891847-Antibodies, Viral,
pubmed-meshheading:8891847-Antiviral Agents,
pubmed-meshheading:8891847-Biological Markers,
pubmed-meshheading:8891847-Biopsy,
pubmed-meshheading:8891847-Chronic Disease,
pubmed-meshheading:8891847-DNA, Viral,
pubmed-meshheading:8891847-Drug Therapy, Combination,
pubmed-meshheading:8891847-Female,
pubmed-meshheading:8891847-Fluorescent Antibody Technique, Indirect,
pubmed-meshheading:8891847-Follow-Up Studies,
pubmed-meshheading:8891847-Hepatitis B,
pubmed-meshheading:8891847-Hepatitis B Surface Antigens,
pubmed-meshheading:8891847-Hepatitis B e Antigens,
pubmed-meshheading:8891847-Hepatitis B virus,
pubmed-meshheading:8891847-Humans,
pubmed-meshheading:8891847-Interferon-alpha,
pubmed-meshheading:8891847-Male,
pubmed-meshheading:8891847-Pregnenediones,
pubmed-meshheading:8891847-Radioimmunoassay,
pubmed-meshheading:8891847-Treatment Outcome,
pubmed-meshheading:8891847-Virus Replication
|
|
pubmed:articleTitle |
Treatment of chronic hepatitis B (HBeAg-HBV DNA-positive) with lymphoblastoid alpha interferon with or without corticosteroids: short- and long-term follow-up.
|
|
pubmed:affiliation |
Divisione di Medicina Generale e Servizio di Epatologia, Ospedale Niguarda, Milano, Italy.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial
|
